Fighting to Preserve the Benefits of the 340B Program
On December 20, 2024, drugmakers Amgen Inc. (Amgen), Eli Lilly and Company (Eli Lilly), and UCB, Inc. (UCB), sued HHS, alleging that HHS has not fulfilled its obligations to oversee…
To close out the year, two federal judges issued conflicting opinions regarding the likelihood of success in challenges to state 340B contract pharmacy laws. In the first major siding with…
What is Changing: Implementation Extended to January 31, 2025: Effective January 31, 2025, Gilead’s Patient Assistance Programs (PAPs), including Advancing Access, will stop providing free medications for medicines where there…
On December 16, Sanofi informed HRSA that it will pause the implementation of its rebate model, termed a “340B credit model.” The same day, Sanofi filed a lawsuit in the…
On December 13th, the Health Resources and Services Administration (HRSA) issued a letter to Sanofi calling for the manufacturer to cease implementation of its rebate model, which Sanofi terms a…
Yesterday, the Supreme Court denied PhRMA’s request for review of the Eighth Circuit’s decision upholding Arkansas Act 1103, which requires delivery of 340B drugs to an unlimited number of contract…
Bristol-Myers Squibb Sues HHS To Implement 340B Rebate Model On November 26, 2024, Bristol-Myers Squibb (BMS) filed a lawsuit against HRSA in the D.C. District Court to defend its proposed…
On November 25, 2024, Sanofi became the third manufacturer to announce its intention to implement a rebate model. Its announcement follows similar announcements from Johnson & Johnson (J&J) and Eli…